Costs and margins
No data available for this market
BRIEF: For the six months ended 30 June 2014, Enzon Pharmaceuticals Inc revenues decreased 8% to $16.7M. Net income increased from $7.1M to $15.4M. Revenues reflect Royalties decrease of 5% to $16.7M, Miscellaneous income decrease of 90% to $62K. Net income reflects General and administrative decrease of 75% to $1.3M (expense), Restructuring charges decrease from $3M (expense) to $0K, Interest expense decrease from $2.1M (expense) to $0K.